A Phase I Study on Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of LP-118 in Patients with Advanced Malignancies
Latest Information Update: 04 Oct 2024
At a glance
- Drugs LP-118 (Primary)
- Indications B-cell lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Guangzhou Lupeng Pharmaceutical
- 30 Sep 2024 Planned End Date changed from 30 Jul 2024 to 30 Dec 2025.
- 30 Sep 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Jan 2025.
- 30 Sep 2024 Status changed from recruiting to active, no longer recruiting.